Bryce Point Capital LLC Purchases Shares of 20,490 Progyny, Inc. (NASDAQ:PGNY)

Bryce Point Capital LLC purchased a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,490 shares of the company's stock, valued at approximately $353,000.

Several other large investors have also recently made changes to their positions in PGNY. Signaturefd LLC grew its stake in Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. GAMMA Investing LLC increased its stake in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares during the period. Nisa Investment Advisors LLC increased its holdings in Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after purchasing an additional 1,526 shares during the period. Caitlin John LLC raised its holdings in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in Progyny in the fourth quarter worth $74,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Stock Performance

PGNY stock traded down $0.64 during midday trading on Thursday, hitting $21.92. 324,845 shares of the company's stock were exchanged, compared to its average volume of 1,720,484. The stock's fifty day moving average price is $22.05 and its 200-day moving average price is $18.61. Progyny, Inc. has a one year low of $13.39 and a one year high of $35.39. The company has a market cap of $1.87 billion, a PE ratio of 37.81, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33.

Remove Ads

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Bank of America lifted their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Canaccord Genuity Group increased their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research report on Monday, March 31st. Finally, JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.